DE69432930D1 - Immunmodulierende zusammensetzungen aus galle - Google Patents

Immunmodulierende zusammensetzungen aus galle

Info

Publication number
DE69432930D1
DE69432930D1 DE69432930T DE69432930T DE69432930D1 DE 69432930 D1 DE69432930 D1 DE 69432930D1 DE 69432930 T DE69432930 T DE 69432930T DE 69432930 T DE69432930 T DE 69432930T DE 69432930 D1 DE69432930 D1 DE 69432930D1
Authority
DE
Germany
Prior art keywords
immunomodulator
composition
relates
galle
immuno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432930T
Other languages
English (en)
Other versions
DE69432930T2 (de
Inventor
Romeo Rang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Erin Mills Biotech Inc
Original Assignee
Lorus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lorus Therapeutics Inc filed Critical Lorus Therapeutics Inc
Application granted granted Critical
Publication of DE69432930D1 publication Critical patent/DE69432930D1/de
Publication of DE69432930T2 publication Critical patent/DE69432930T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69432930T 1993-09-09 1994-09-09 Immunmodulierende zusammensetzungen aus galle Expired - Lifetime DE69432930T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11826993A 1993-09-09 1993-09-09
US118269 1993-09-09
US15530393A 1993-11-22 1993-11-22
US155303 1993-11-22
US23172694A 1994-04-22 1994-04-22
US231726 1994-04-22
PCT/CA1994/000494 WO1995007089A1 (en) 1993-09-09 1994-09-09 Immunomodulating compositions from bile

Publications (2)

Publication Number Publication Date
DE69432930D1 true DE69432930D1 (de) 2003-08-14
DE69432930T2 DE69432930T2 (de) 2004-05-06

Family

ID=27382133

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432930T Expired - Lifetime DE69432930T2 (de) 1993-09-09 1994-09-09 Immunmodulierende zusammensetzungen aus galle

Country Status (15)

Country Link
US (1) US6280774B1 (de)
EP (1) EP0717631B1 (de)
JP (1) JP4708511B2 (de)
KR (1) KR100260110B1 (de)
CN (1) CN1132586C (de)
AT (1) ATE244570T1 (de)
AU (1) AU7648994A (de)
CA (1) CA2171281C (de)
DE (1) DE69432930T2 (de)
ES (1) ES2207639T3 (de)
FI (1) FI961109A (de)
HK (1) HK1007922A1 (de)
NO (1) NO960907L (de)
NZ (1) NZ273258A (de)
WO (1) WO1995007089A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711294B2 (en) * 1995-03-16 1999-10-07 Erin Mills Biotech Inc. Immunomodulating compositions from bile for the treatment of immune system disorders
ATE304864T1 (de) 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
CA2206047A1 (en) * 1997-05-23 1998-11-23 Romeo Rang (Deceased) Immunomodulating compositions for the treatment of viral disorders
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
WO2002038164A1 (en) * 2000-11-08 2002-05-16 Lorus Therapeutics Inc. Combination preparation of a biological response modifier and an anticancer agent and uses thereof
ITRM20010688A1 (it) * 2001-11-21 2003-05-21 Univ Roma Composti immunoregolatori.
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US9717754B2 (en) 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
JP4274469B2 (ja) * 2004-01-20 2009-06-10 Ｏｋｉセミコンダクタ株式会社 データ取り込みクロック補正回路
EP1863520B1 (de) 2005-03-08 2014-12-31 Aptose Biosciences Inc. Verwendung von interleukin 17e zur behandlung von krebs
GB0513431D0 (en) * 2005-06-30 2005-08-10 Kherion Technology Ltd Prophylactic compositions and uses
CN101629951B (zh) * 2009-08-20 2013-01-02 吴广印 一种人胎盘组织液抗炎作用检测方法
US8236354B1 (en) 2012-02-17 2012-08-07 ZOR Pharmaceuticals, LLC Use of immunomodulators for the treatment of cancer
US8338383B1 (en) 2012-02-17 2012-12-25 Gregory Jr Daniel Tyree Use of immunomodulators for the treatment of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4562179A (en) 1982-04-19 1985-12-31 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, and pharmaceutical composition of the same
US4585762A (en) 1982-07-30 1986-04-29 Fujisawa Pharmaceutical Co., Ltd. Phospholipid derivatives, processes for use thereof and pharmaceutical composition of the same
JPS5984824A (ja) 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
US4767610A (en) 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US4916249A (en) 1985-07-03 1990-04-10 Hans Brachwitz Glycero-3(2)-phospho-L-serine derivatives and salts thereof
IE59777B1 (en) 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
GB8706313D0 (en) * 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US4965391A (en) 1987-10-23 1990-10-23 The University Of Michigan Radioiodinated phospholipid ether analogues
US5087721A (en) 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
US5138067A (en) 1987-12-17 1992-08-11 Shionogi & Co. Ltd. Lipid derivatives
EP0397774A1 (de) * 1988-02-04 1990-11-22 Board Of Regents, The University Of Texas System Formulierung und anwendung von retinoiden für behandlung von krebs und anderen krankheiten
EP0356765A3 (de) 1988-08-19 1991-08-07 Takeda Chemical Industries, Ltd. Carbonsäurederivate, deren Herstellung und Verwendung
EP0378763A1 (de) 1988-10-27 1990-07-25 Takeda Chemical Industries, Ltd. Lipide, ihre Herstellung und Verwendung
US5109118A (en) 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
GB8928580D0 (en) 1989-12-19 1990-02-21 Scras 3-(n-methyl-n-alkylamino)-methoxymethyl-propanol phosphocholine derivatives
US5369097A (en) 1991-04-25 1994-11-29 The University Of British Columbia Phosphonates as anti-cancer agents

Also Published As

Publication number Publication date
US6280774B1 (en) 2001-08-28
DE69432930T2 (de) 2004-05-06
JPH09502706A (ja) 1997-03-18
CN1132586C (zh) 2003-12-31
EP0717631B1 (de) 2003-07-09
EP0717631A1 (de) 1996-06-26
FI961109A0 (fi) 1996-03-08
ATE244570T1 (de) 2003-07-15
CA2171281A1 (en) 1995-03-16
FI961109A (fi) 1996-05-06
WO1995007089A1 (en) 1995-03-16
HK1007922A1 (en) 1999-04-30
NZ273258A (en) 2000-01-28
AU7648994A (en) 1995-03-27
NO960907D0 (no) 1996-03-06
KR100260110B1 (ko) 2000-07-01
CN1136777A (zh) 1996-11-27
CA2171281C (en) 1998-12-29
NO960907L (no) 1996-04-30
ES2207639T3 (es) 2004-06-01
JP4708511B2 (ja) 2011-06-22

Similar Documents

Publication Publication Date Title
DE69432930D1 (de) Immunmodulierende zusammensetzungen aus galle
Espevik et al. Inhibition of cytokine production by cyclosporin A and transforming growth factor beta.
Yaron et al. Some recombinant human cytokines stimulate glycosaminoglycan synthesis in human synovial fibroblast cultures and inhibit it in human articular cartilage cultures
NO974257L (no) Immunomodulerende preparater fra galle for behandling av immunsystemsykdommer
JO1365B1 (en) Laoxy repo nucleic polypeptide acid has a physiological activity on humans and includes a basic sequence for the coded arrangement of the said polypeptide and a method for producing this for polypeptide and the pharmacological composition included.
MX9602259A (es) Proteina modificada quimicamente en el nitrogeno terminal, composiciones que las incluyen y metodos para su preparacion.
BRPI0317064B8 (pt) composições compreendendo células dendríticas parcialmente amadurecidas in vitro
Parker et al. Presence of IL-1 receptors on human and murine neutrophils. Relevance to IL-1-mediated effects in inflammation.
Choe et al. Effect of lactoferrin on the production of tumor necrosis factor‐α and nitric oxide
HK1029330A1 (en) N-hydroxyformamide derivatives
Seckinger et al. Modulation of the effects of interleukin‐1 on glycosaminoglycan synthesis by the urine‐derived interleukin‐1 inhibitor, but not by interleukin‐6
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
WO1997028255B1 (en) Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
Kapp et al. Granulocyte-activating mediators (GRAM) II. Generation by human epidermal cells-relation to GM-CSF
CA2017315C (en) Interleukin i inhibitor
Klasing et al. Monokine‐like activities released from a chicken macrophage line
Magielska-Zero et al. Comparison of the acute phase response of cultured Morris hepatoma 7777 cells and of rat hepatocytes.
Hirai et al. Characterization of a human basophil-like cell promoting activity.
CA2266743A1 (en) Adenoviral vectors for mutants of human interleukin 6 (hil-6) with hil-6 antagonist activity, pharmaceutical compositions therewith and their uses
MX9709361A (es) Monomero de 4.4-ciclohexan-1-ols disubstituido y compuestos relacionados.
US5216133A (en) Human monocyte growth factor
Tadokoro et al. Further biochemical characterization of human basophil-like cell-promoting activity and its distinction from human interleukin-3-like activity
Schlunk et al. Preparative purification of human placental colony-stimulating factors
ZA9510878B (en) 4,4-(Disubstituted)cyclohexan-1-ols monomers and related compounds
Dinarello et al. Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GENESENSE TECHNOLOGIES INC., TORONTO, ONTARIO, CA

8327 Change in the person/name/address of the patent owner

Owner name: LORUS THERAPEUTICS INC., TORONTO, ONTARIO, CA

8327 Change in the person/name/address of the patent owner

Owner name: ERIN MILLS BIOTECH INC., CONCORD, ONTARIO, CA